Biotechnology company United Therapeutics (NASDAQ: UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 million. Its non-GAAP profit of $7.27 per share was 3.5% above analysts’ consensus estimates.

Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized progress in the company’s clinical programs, particularly the ADVANCE OUTCOMES study for ralinepag and the TETON-1 trial for Tyvaso in pulmonary fibrosis. President Michael Benkowitz noted that although revenue was flat sequentially, operational momentum improved, driven by record patient metrics and recent sales force expansion. Management acknowledged that more time is needed for the benefits of differentiated therapies to become evident to physicians.

Looking forward, United Therapeutics’ outlook is anchored in anticipated regulatory milestones and new product launches, with management describing upcoming approvals for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and ralinepag in pulmonary arterial hypertension (PAH) as multibillion-dollar catalysts. Benkowitz stated, “We expect the second half of 2026 to be stronger than the first half,” while Rothblatt outlined the company’s plans for additional regulatory filings and potential market expansion through novel inhalation devices. Management also highlighted broader ambitions in organ transplantation and regenerative medicine following the Thymmune Therapeutics acquisition.

Key Insights from Management’s Remarks

Management attributed second quarter performance to ongoing competitive challenges in core markets, but underscored substantial advances in clinical development and commercial capabilities.

• Competitive market dynamics: The inhaled prostacyclin category, particularly for nebulized Tyvaso, experienced increased competition as more treatment options became available, impacting short-term sales and market share.
• Tyvaso DPI momentum: Despite pressures on the nebulized formulation, Tyvaso DPI (dry powder inhaler) saw record levels in patient starts, referrals, and commercial adoption, signaling growing franchise durability.
• Expanded sales force: The company roughly doubled its sales team, deploying new representatives in July to expand community reach for pulmonary hypertension (PAH) and interstitial lung disease (PH-ILD), aiming to accelerate adoption and physician engagement.
• Pipeline milestones: Positive results from the ADVANCE OUTCOMES (ralinepag in PAH) and TETON-1 (Tyvaso in IPF) studies led to major regulatory submissions, including a new drug application (NDA) for ralinepag and a supplemental NDA for Tyvaso in IPF.
• Strategic acquisition: The acquisition of Thymmune Therapeutics broadened United Therapeutics’ regenerative medicine platform, strengthening its organ alternative strategy and supporting long-term growth ambitions.

Drivers of Future Performance

United Therapeutics’ forward guidance is shaped by expectations for new drug approvals, franchise expansion, and ongoing commercial initiatives, while management remains mindful of regulatory and competitive risks.

• Upcoming product launches: Management anticipates regulatory approvals for nebulized Tyvaso in IPF and ralinepag in PAH in 2027, which are expected to drive significant revenue growth and expand the company’s presence in rare pulmonary diseases.
• Sales force and commercial execution: The expanded sales force is expected to increase physician awareness and support stronger uptake of both existing and future therapies, particularly as the market shifts toward a polytherapy approach in IPF and other indications.
• Pipeline and regulatory milestones: Future growth depends on the success of ongoing clinical trials, such as TETON-PPF for pulmonary fibrosis, and the timely approval of additional inhalation devices, with management noting that regulatory review periods and bridging study requirements could affect launch timing and market access.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will be watching (1) progress on regulatory review and potential approval timelines for ralinepag and nebulized Tyvaso in new indications, (2) the impact of the expanded sales force on commercial performance and physician adoption, and (3) updates on clinical trial milestones, especially the TETON-PPF readout. Execution in organ transplantation and integration of Thymmune Therapeutics will also be important markers of long-term strategy.

United Therapeutics currently trades at $518.65, in line with $518.68 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.